Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients
Authors:
- Satohiro MasudaSatohiro Masuda
- Toshiya KatsuraTKToshiya Katsura
- Fumitaka OikeFOFumitaka Oike
- Yasutsugu TakadaYTYasutsugu Takada
- Ken-Ichi InuiKIKen-Ichi Inui
- 1 February 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 16 (2) , 119-127
Abstract
It has been reported that hepatic and intestinal cytochrome P450 (CYP) 3A4, CYP3A5 and P-glycoprotein affect the pharmacokinetics of tacrolimus, and that these proteins are associated with the large inter-individual variation in the pharmacokinetics of this drug. We previously showed that the concentration/dose ratio of tacrolimus tended to be lower in recipients of living-donor liver transplantation (LDLT) with a CYP3A5*1/*1-carrying graft. However, the effect of intestinal CYP3A5 remains to be elucidated. In the present study, we examined the CYP3A5 genotype in both recipients and donors, and the effect of the recipients' polymorphism on the concentration/dose ratio of tacrolimus in patients after LDLT. The CYP3A5*3 allele frequency was 80% in recipients and 77% in donors. The intestinal CYP3A5 mRNA expression level was significantly associated with genotype. The tacrolimus concentration/dose ratio was lower in recipients with the CYP3A5*1/*1 and *1/*3 genotype (CYP3A5 expressors) compared to the CYP3A5*3/*3 genotype (non-expressors). Amongst the combination of CYP3A5 genotypes between the graft liver and the native intestine, CYP3A5 expressors in both the graft liver and the native intestine had the lowest concentration/dose ratio of tacrolimus during 35 days after LDLT. Patients with the intestinal CYP3A5*1 genotype tended to require a higher dose of tacrolimus compared to the other group with the same hepatic CYP3A5 genotype. These results indicate that intestinal CYP3A5, as well as hepatic CYP3A5, plays an important role in the first-pass effect of orally administered tacrolimus.Keywords
This publication has 29 references indexed in Scilit:
- Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South AsiansTransplantation, 2005
- CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantationPharmacogenetics, 2004
- Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients1 2Transplantation, 2003
- Novel detection assay by PCR???RFLP and frequency of the CYP3A5 SNPs, CYP3A5 *3 and *6, in a Japanese populationPharmacogenetics, 2002
- Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living‐donor liver transplantationClinical Pharmacology & Therapeutics, 2001
- Immunosuppressive strategies in transplantationThe Lancet, 1999
- Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug deliveryAdvanced Drug Delivery Reviews, 1997
- Clinical Pharmacokinetics of TacrolimusClinical Pharmacokinetics, 1995
- Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomesBiochemical Pharmacology, 1994
- Surgical Techniques and Innovations in Living Related Liver TransplantationAnnals of Surgery, 1993